跳至主要内容
临床试验/NL-OMON30237
NL-OMON30237尚未招募不适用

Does caffeine reduce dipyridamole-induced protection against ischemia-reperfusion injury? - dipy001

niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • healthy males, age between 18-50yr

排除标准

  • -any concomittant medication
  • -cardiovascular disease
  • -hypertension (systole > 140 mmHg, diastole > 90 mmHg)
  • -hypercholesterolemia (fasting total cholesterol > 5 mmol/l)
  • -diabetes mellitus (fasting glucose > 7.0 mmol/L or random glucose > 11.0 mmol/L)
  • -asthma(recurrent episodes of dyspnea and wheezing, or usage of prescribed medications: inhalation corticosteroids or B2-agonists)
  • -participation in any clinical trial during the last 60 days prior to this study.
  • -administration of two doses of Annexin A5 (0,1mg; 450MBq) during the last 5 years prior to this study.

研究者

发起方
niversitair Medisch Centrum Sint Radboud

相似试验

Does caffeine reduce dipyridamole-induced protection... | 临床试验